UBS Asset Management Americas Inc. Boosts Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

UBS Asset Management Americas Inc. boosted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 7.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 149,375 shares of the company’s stock after buying an additional 10,600 shares during the period. UBS Asset Management Americas Inc. owned 0.33% of Amphastar Pharmaceuticals worth $2,166,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMPH. Trexquant Investment LP acquired a new position in Amphastar Pharmaceuticals during the fourth quarter worth about $197,000. Louisiana State Employees Retirement System increased its position in Amphastar Pharmaceuticals by 1.4% in the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the company’s stock worth $212,000 after buying an additional 200 shares during the last quarter. Thrivent Financial for Lutherans increased its position in Amphastar Pharmaceuticals by 2.1% in the fourth quarter. Thrivent Financial for Lutherans now owns 19,440 shares of the company’s stock worth $358,000 after buying an additional 400 shares during the last quarter. New York State Teachers Retirement System increased its position in Amphastar Pharmaceuticals by 43.2% in the fourth quarter. New York State Teachers Retirement System now owns 19,896 shares of the company’s stock worth $366,000 after buying an additional 6,000 shares during the last quarter. Finally, Boston Advisors LLC increased its position in Amphastar Pharmaceuticals by 21.9% in the first quarter. Boston Advisors LLC now owns 37,340 shares of the company’s stock worth $541,000 after buying an additional 6,700 shares during the last quarter. 45.32% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) traded down 0.67% during mid-day trading on Tuesday, hitting $17.83. 13,043 shares of the company traded hands. Amphastar Pharmaceuticals, Inc. has a one year low of $12.05 and a one year high of $21.75. The company’s 50-day moving average price is $16.62 and its 200 day moving average price is $16.18. The company has a market capitalization of $815.49 million, a price-to-earnings ratio of 93.84 and a beta of 1.68.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Monday, May 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.06 by $0.03. The business had revenue of $56.67 million for the quarter, compared to the consensus estimate of $63.74 million. Amphastar Pharmaceuticals had a return on equity of 2.69% and a net margin of 3.54%. Amphastar Pharmaceuticals’s revenue was down 4.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.12 earnings per share. On average, analysts anticipate that Amphastar Pharmaceuticals, Inc. will post $0.40 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “UBS Asset Management Americas Inc. Boosts Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/07/18/ubs-asset-management-americas-inc-has-2-17-million-stake-in-amphastar-pharmaceuticals-inc-nasdaqamph-updated.html.

Several analysts recently weighed in on the stock. Jefferies Group LLC set a $21.00 price objective on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, April 20th. TheStreet upgraded shares of Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Monday, June 26th. Finally, Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, May 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $20.14.

In other news, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $17.07, for a total transaction of $170,700.00. Following the sale, the director now directly owns 28,844 shares of the company’s stock, valued at $492,367.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard K. Prins sold 7,500 shares of the company’s stock in a transaction on Thursday, May 11th. The stock was sold at an average price of $15.43, for a total value of $115,725.00. Following the sale, the director now owns 30,500 shares of the company’s stock, valued at approximately $470,615. The disclosure for this sale can be found here. Insiders have sold a total of 43,982 shares of company stock valued at $735,850 over the last ninety days. Company insiders own 11.10% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply